Weekly Recap | KEYMED BIO-B -4.12%, most brokers rate it buyWeekly Review·Nov 14, 2026 at 05:17 AM02162-3.51%
JPM Initiates KEYMED BIO-B at Overweight, TP at HKD95AASTOCKS News·Nov 9, 2026 at 03:40 AM02162-3.51%
Weekly Recap | KEYMED BIO-B +4.13%, large-lot money turns net sellerWeekly Review·Nov 7, 2026 at 05:43 AM02162-3.51%
Chinese Cancer Drugmakers Raise Global Stakes With Record Oncology Congress ShowingYicai·Oct 28, 2026 at 11:53 AMHCM-2.24%HAWG-0.82%
CLSA: KEYMED BIO-B Plunged 14% on Tue, Likely Due to Weak Market SentimentAASTOCKS News·Oct 28, 2026 at 04:38 AM02162-3.51%
A USD 90 Million Upfront Anchors Hong Kong Biotech's December RushGlobal Report·Oct 28, 2026 at 03:45 AM02269-5.10%02268-4.52%
Keymed-B (2162.HK) falls 3% in Hong Kong tradingHK Stock Market Update·Oct 27, 2026 at 01:36 AM02162-3.51%
HSBC Research: US COINS Act Proposes Curbs on Investment in China's Biotech Sector, but BD Deals UnaffectedAASTOCKS News·Oct 26, 2026 at 08:20 AM01801-3.61%02162-3.51%
Weekly Recap | KEYMED BIO-B -0.37%, most brokers rate it buyWeekly Review·Oct 24, 2026 at 05:16 AM02162-3.51%
M Stanley: Outlook for 4Q26 Catalysts in China Biotech Stocks; Sector Rated "Attractive"AASTOCKS News·Oct 23, 2026 at 05:35 AM01801-3.61%02162-3.51%
Biotech Breakthroughs and AI Surge Fuel Hong Kong Small-Cap ResilienceGlobal Report·Oct 21, 2026 at 09:17 AM02162-3.51%001170.00%
Weekly Recap | KEYMED BIO-B +2.57%, revenue up over two-foldWeekly Review·Oct 17, 2026 at 05:40 AM02162-3.51%